Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Robert, Caroline, Prof ; Ribas, Antoni, Prof ; Schachter, Jacob, Prof ; Arance, Ana, MD ; Grob, Jean-Jacques, Prof ; Mortier, Laurent, Prof ; Daud, Adil, Prof ; Carlino, Matteo S, MB ; McNeil, Catriona M, MD ; Lotem, Michal, Prof ; Larkin, James M G, Prof ; Lorigan, Paul, Prof ; Neyns, Bart, Prof ; Blank, Christian U, Prof ; Petrella, Teresa M, MD ; Hamid, Omid, MD ; Su, Shu-Chih, PhD ; Krepler, Clemens, MD ; Ibrahim, Nageatte, MD ; Long, Georgina V, Prof

The lancet oncology, 2019-09, Vol.20 (9), p.1239-1251 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível